Mallinckrodt to Report Earnings Results for Third Quarter 2024
Mallinckrodt announced it will release its third quarter 2024 financial results on Tuesday, November 5, 2024. The global specialty pharmaceutical company will host an investor conference call at 8:30 a.m. ET on the same day to discuss the results for the period ended September 27, 2024. The company has provided multiple access options for interested parties, including a dial-in registration link, an audio webcast, and access through the corporate website.
Mallinckrodt ha annunciato che pubblicherà i risultati finanziari del terzo trimestre 2024 martedì 5 novembre 2024. La società farmaceutica specializzata a livello globale ospiterà una conference call per gli investitori alle 8:30 a.m. ET dello stesso giorno per discutere i risultati del periodo conclusosi il 27 settembre 2024. L'azienda ha fornito diverse opzioni di accesso per le parti interessate, inclusi un link per la registrazione telefonica, una trasmissione audio e l'accesso tramite il sito web aziendale.
Mallinckrodt anunció que publicará sus resultados financieros del tercer trimestre de 2024 el martes 5 de noviembre de 2024. La compañía farmacéutica especializada a nivel mundial llevará a cabo una llamada de conferencia para inversores a las 8:30 a.m. ET el mismo día para discutir los resultados del período que finalizó el 27 de septiembre de 2024. La empresa ha proporcionado múltiples opciones de acceso para las partes interesadas, que incluyen un enlace para registro telefónico, una transmisión de audio y acceso a través del sitio web corporativo.
말린크로트는 2024년 3분기 재무 결과를 2024년 11월 5일 화요일에 발표할 것이라고 발표했습니다. 글로벌 전문 제약 회사는 같은 날 오전 8시 30분 ET에 투자자 컨퍼런스 콜을 진행하여 2024년 9월 27일 종료된 기간에 대한 결과를 논의할 예정입니다. 회사는 관심 있는 당사자를 위해 전화 등록 링크, 오디오 웹캐스트 및 기업 웹사이트를 통한 접근 등 여러 접근 옵션을 제공했습니다.
Mallinckrodt a annoncé qu'il publiera ses résultats financiers pour le troisième trimestre 2024 le mardi 5 novembre 2024. La société pharmaceutique spécialisée à l'échelle mondiale organisera une conférence téléphonique pour les investisseurs à 8h30 ET le même jour pour discuter des résultats pour la période se terminant le 27 septembre 2024. L'entreprise a fourni plusieurs options d'accès pour les parties intéressées, y compris un lien d'inscription par téléphone, un webinaire audio et un accès via le site Web de l'entreprise.
Mallinckrodt hat bekannt gegeben, dass es am Dienstag, den 5. November 2024 seine finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das globale Spezialpharma-Unternehmen wird am selben Tag um 8:30 Uhr ET eine Investorenkonferenzschaltung abhalten, um die Ergebnisse für den zum 27. September 2024 abgeschlossenen Zeitraum zu besprechen. Das Unternehmen hat mehrere Zugangsmöglichkeiten für interessierte Parteien bereitgestellt, darunter einen Registrierungslink für Telefonanrufe, ein Audio-Webcast und Zugang über die Unternehmenswebsite.
- None.
- None.
A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows:
- Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BI60bb36abdb99465c9db5640f3457528a
- Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/6tqaksqg/
- At the Mallinckrodt website: https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the
CONTACTS
Investor Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-third-quarter-2024-302285276.html
SOURCE Mallinckrodt plc
FAQ
When will Mallinckrodt (MNK) report Q3 2024 earnings?
What time is Mallinckrodt's (MNK) Q3 2024 earnings call?
How can I access Mallinckrodt's (MNK) Q3 2024 earnings call?
